The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Epigenetic plasticity and the hallmarks of cancer
Open accessAbstract
Cancer epigenetics in the driver's seat: Recent cancer genome projects unexpectedly highlighted the role of epigenetic alterations in cancer development. About half of human cancers were found to harbor mutations in chromatin proteins. In a Review, Flavahan et al. propose that chromatin and epigenetic aberrations have the potential to confer on cells the full range of oncogenic properties represented in the classic “hallmarks” depiction of cancer. They suggest that genetic, environmental, and metabolic factors can make chromatin aberrantly permissive or restrictive. Permissive chromatin creates a state of “epigenetic plasticity,” which can activate oncogene expression or cell fate changes that drive cancer development. Science , this issue p. eaal2380
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in chromatin state have been associated with many diseases including several cancers1.”
From Profiling the genetic determinants of chromatin accessibility with scalable single-cell CRISPR screens (2021) · cites this paper as [1]
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping
Rao, S. S. P., Huntley, M. H., Durand, N. C., Stamenova, E. K., Bochkov, I. D., Robinson, J. T., Sanborn, A. L., Machol, I., Omer, A. D., Lander, E. S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.021 · Cited by 9,212
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Self-citationJones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,001
Ismail, J. N., Ghannam, M., Outa, A. A., Frey, F., & Shirinian, M. (2020) · Epigenetics · doi:10.1080/15592294.2020.1767323 · Cited by 16
Alarcón, T., Josep Sardanyés, A., Guillamon, A., & Menéndez, J. A. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008408 · Cited by 15
Oral microbiota: the overlooked catalyst in cancer initiation and progression
Wang, X., He, X., & Zhong, B. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1479720 · Cited by 15
Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming
Zhao, T., He, L., Wong, L. P., Mei, S., Xia, J., Xu, Y., Vranken, J. G. V., Mazzola, M. C., Chen, L., Rhee, C., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.05.009 · Cited by 14
Epigenetic regulation of mechanotransduction
Stowers, R. S., & Chaudhuri, O. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00678-6 · Cited by 14
Gene-circuit therapy on the horizon: synthetic biology tools for engineered therapeutics
Krzysztoń, R., Wan, Y., Petreczky, J., & Balázsi, G. (2021) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5744 · Cited by 18
To bind or not to bind: Cistromic reprogramming in prostate cancer
Shen, M., Demers, L.-K., Bailey, S. D., & Labbé, D. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.963007 · Cited by 15
Heterogeneity of the tumor immune microenvironment and clinical interventions
Jin, Z., Zhou, Q., Cheng, J., Jia, Q., & Zhu, B. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1015-9 · Cited by 14
Cooperation of MLL1 and Jun in controlling H3K4me3 on enhancers in colorectal cancer
Lin, X., Chen, J., Wang, C.-Y., Cai, Z., Zhan, R., Chen, Y., Zhang, L.-Y., Li, L., Xiao, Y., Chen, M., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03108-3 · Cited by 14
Identification and characterization of CLEC11A and its derived immune signature in gastric cancer
Zheng, Q. Y., Gong, Z., Li, B., Cheng, R., Luo, W., Huang, C., & Wang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1324959 · Cited by 14
Cell of origin epigenetic priming determines susceptibility to Tet2 mutation
Schiroli, G., Kartha, V. K., Duarte, F. M., Kristiansen, T. A., Mayerhofer, C., Shrestha, R., Earl, A., Hu, Y., Tay, T., Rhee, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48508-6 · Cited by 15
Yan, Z., Liu, Y., & Yuan, Y. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02275-x · Cited by 14
Naciri, I., Laisné, M., Ferry, L., Bourmaud, M., Gupta, N., Carlo, S. E. D., Huna, A., Martin, N., Peduto, L., Bernard, D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz080 · Cited by 14
Li, J., Hu, J., Luo, Z., Zhou, C., Huang, L., Zhang, H., Chi, J., Chen, Z., Li, Q., Deng, M., et al. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111644 · Cited by 14
Wang, Q., Jiang, S., Liu, J., Ma, G., Zheng, J., & Zhang, Y. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3460 · Cited by 14
Charting differentially methylated regions in cancer with Rocker-meth
Benelli, M., Franceschini, G. M., Magi, A., Romagnoli, D., Biagioni, C., Migliaccio, I., Malorni, L., & Demichelis, F. (2021) · Communications Biology · doi:10.1038/s42003-021-02761-3 · Cited by 14
DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300
Kim, H. J., Moon, S. J., Hong, S., Won, H., & Kim, J. H. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac585 · Cited by 14
Epistasis and evolutionary dependencies in human cancers
Mina, M., Iyer, A., & Ciriello, G. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101989 · Cited by 13
Bhandari, Y. R., Krishna, V., Powers, R., Parmar, S., Thursby, S.-J., Gupta, E., Kulak, O., Gokare, P. R., Reumers, J., Wesenbeeck, L. V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301536120 · Cited by 15
Loss of the chromatin modifier Kdm2aa causes BrafV600E-independent spontaneous melanoma in zebrafish
Scahill, C. M., Digby, Z., Sealy, I. M., Wojciechowska, S., White, R. J., Collins, J. E., Stemple, D. L., Bartke, T., Mathers, M. E., Patton, E. E., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006959 · Cited by 14
WHSC1 acts as a prognostic indicator and functions as an oncogene in cervical cancer
Wu, J., Luo, M., Duan, Z., Jia, Y., Linghu, H., Tian, P., & Qi, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s204701 · Cited by 14
Zhou, Y., Xiong, K., Feng, T., Wu, X., Liang, J., Chen, Y., & Chao, H. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202504970 · Cited by 13
Mapping intratumor heterogeneity across layers for advancing immunotherapy
Marine, J., Bartok, O., Sagie, S., Vitiello, P. P., Bardelli, A., Weller, C., Chang, T., Tonelli, C., Spranger, S., Ruppin, E., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.025 · Cited by 16
The epigenome and the many facets of cancer drug tolerance
Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 14
Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma
Parsels, L. A., Wahl, D. R., Koschmann, C. J., Morgan, M. A., & Zhang, Q. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100881 · Cited by 12
Zhao, Z., Chen, Y., Cheng, X., Huang, L., Wen, H., Xu, Q., Zhou, X., Zhang, X., Chen, J., & Ni, T. (2023) · Science Advances · doi:10.1126/sciadv.adf3264 · Cited by 12
Zeng, Z., Li, Z., Xue, J., Xue, H., Liu, Z., Zhang, W., Liu, H., & Xu, S. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01418-w · Cited by 13
Crol contributes to PRE-mediated repression and Polycomb group proteins recruitment inDrosophila
Erokhin, M., Brown, J. L., Ломаев, Д. В., Vorobyeva, N. E., Zhang, L., Fab, L. V., Mazina, M. Y., Kulakovskiy, I. V., Ziganshin, R., Schedl, P. D., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad336 · Cited by 14
Pinton, A., Courtois, L., Doublet, C., Cabannes‐Hamy, A., Andrieu, G. P., Smith, C. L., Balducci, E., Cieślak, A., Touzart, A., Simonin, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2159 · Cited by 15
MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells
Daimon, T., Bhattacharya, A., Wang, K., Haratake, N., Nakashoji, A., Ozawa, H., Morimoto, Y., Yamashita, N., Kosaka, T., Oya, M., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01772-9 · Cited by 12
Bridging tissue repair and epithelial carcinogenesis: epigenetic memory and field cancerization
Levron, C. L., Elettrico, L., Duval, C., Piacenti, G., Proserpio, V., & Donati, G. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-023-01254-6 · Cited by 15
Extrachromosomal circular DNA (eccDNA): from carcinogenesis to drug resistance
Li, Z., & Qian, D. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01348-6 · Cited by 14
Huang, C., Zhao, C., Sun, Y., Feng, T., Ren, J., & Qu, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c01794 · Cited by 13
The Wdr5-H3K4me3 Epigenetic Axis Regulates Pancreatic Tumor Immunogenicity and Immune Suppression
Deng, K., Liang, L., Yang, Y., Wu, Y., Li, Y., Zhang, R., Sheng, G., Tian, Y., & Lu, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168773 · Cited by 13
Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review
Arshi, A., Mahmoudi, E., Raeisi, F., Tezerjani, M. D., Bahramian, E., Ahmed, Y., & Peng, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1446937 · Cited by 13
Lu, M., Zhang, X., Yun, X., He, G., Liu, Q., Zhu, J., & Zhang, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25663 · Cited by 13
Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase
Trager, M. H., Sah, B., Chen, Z., & Liu, L. (2021) · Endocrinology · doi:10.1210/endocr/bqab088 · Cited by 13
Singh, R., & Mills, I. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704353 · Cited by 13
Elevated METTL9 is associated with peritoneal dissemination in human scirrhous gastric cancers
Hara, T., Tominaga, Y., Ueda, K., Mihara, K., Yanagihara, K., & Takei, Y. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101255 · Cited by 13
KRAB-ZFPs and cancer stem cells identity
Olechnowicz, A., Oleksiewicz, U., & Machnik, M. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.03.013 · Cited by 14
Personalized Medicine in Practice: Postgenomics from Multiplicity to Immutability
Chorev, N. E. (2019) · Body & Society · doi:10.1177/1357034x19886925 · Cited by 13
A Devil of a Transmissible Cancer
Woods, G. M., Lyons, A. B., & Bettiol, S. S. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5020050 · Cited by 13
The LL-100 Cell Lines Panel: Tool for Molecular Leukemia–Lymphoma Research
Drexler, H. G., & Quentmeier, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165800 · Cited by 15
Single-Cell Transcriptome Identifies the Renal Cell Type Tropism of Human BK Polyomavirus
Feng, Y., Chen, X., Zhang, H., Zhao, G.-D., Yang, H.-F., Qiu, J., Meng, S., Wu, P., Tao, L., Wang, Q., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021330 · Cited by 13
Holanda, R. D. B. F., Leite, G. G. F., Brunialti, M. K. C., Jasiulionis, M. G., & Salomão, R. (2023) · Shock · doi:10.1097/shk.0000000000002131 · Cited by 12
Wang, D., Zu, Y., Sun, W., & Fan, X. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230525143252 · Cited by 13
Guo, Y., Shen, R., Yang, K., Wang, Y., Song, H., Liu, X., Cheng, X., Wu, R., Song, Y., & Wang, D. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01500-3 · Cited by 12
Hassan, M., Tutar, L., Sari, D., Rasul, A., Basheer, E., & Tutar, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102055 · Cited by 12
ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer
Diciaccio, B., Seehawer, M., Li, Z., Patmanidis, A., Bui, T. M., Foidart, P., Nishida, J., D’Santos, C. S., Papachristou, E. K., Papanastasiou, M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114991 · Cited by 12
A tale of two strands: Decoding chromatin replication through strand-specific sequencing
Li, Z., & Zhang, Z. (2025) · Molecular Cell · doi:10.1016/j.molcel.2024.10.035 · Cited by 13
Quantifying the interplay between genetic and epigenetic regulations in stem cell development
Zhang, Y., Liu, N., Lin, W. J., & Li, C. (2019) · New Journal of Physics · doi:10.1088/1367-2630/ab4c82 · Cited by 12
Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer
Li, Y., Meng, L., Shi, T., Ren, J., & Deng, Q. (2020) · Cell Biology International · doi:10.1002/cbin.11474 · Cited by 12
Thy, S., Hommel, A., Meneceur, S., Bartkowiak, A. L., Schulz, W. A., Niegisch, G., & Hoffmann, M. J. (2021) · Cancers · doi:10.3390/cancers13061376 · Cited by 12
Why is PAK4 overexpressed in cancer?
Costa, T. D. F., & Strömblad, S. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106041 · Cited by 12
Epigenetic instability may alter cell state transitions and anticancer drug resistance
Saini, A., & Gallo, J. M. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009307 · Cited by 12
Osman, N. M., Shawky, A.-E.-M., & Bryliński, M. (2022) · BMC Genomic Data · doi:10.1186/s12863-021-01021-x · Cited by 11
Role of Oral Microbiota in Carcinogenesis: A Short Review
Issrani, R., Reddy, J., El‐Metwally, T. H., & Prabhu, N. (2022) · Journal of Cancer Prevention · doi:10.15430/jcp.2022.27.1.16 · Cited by 12
Wang, H., Song, Z., Xie, E., Chen, J., Tang, B., Wang, F., & Min, J. (2022) · Research · doi:10.34133/2022/9814652 · Cited by 14
Ying, T., Wang, X., Yao, Y., Yuan, J., Chen, S., Wen, L., Chen, Z., Wang, X., Luo, C., Sheng, J., et al. (2022) · Cancers · doi:10.3390/cancers15010243 · Cited by 12
Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery
Kamath, D. V., Iwakuma, T., & Bossmann, S. H. (2024) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2024.102732 · Cited by 13
Moisoiu, V., Sas, V., Ştefancu, A., Iancu, Ș. D., Jurj, A. M., Paşca, S., Iluta, S., Zimța, A., Țigu, A. B., Teodorescu, P., et al. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.703268 · Cited by 12
Ortega-Sabater, C., Calvo, G. F., Dinić, J., Podolski-Renić, A., Pešić, M., & Pérez‐García, V. M. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-022-01113-4 · Cited by 12
Su, Y., Liu, C., Lu, X., Li, G., Shao, S., Kong, Y., Lee, J. W., Ng, R. H., Wong, S. K., Robert, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724740 · Cited by 12
Pierce, B. L. (2022) · eLife · doi:10.7554/elife.78693 · Cited by 12
Epigenetic mechanisms in HCC immune landscape: Therapeutic implications
Fernández‐Barrena, M. G., Uriarte, I., Sarobe, P., & Avila, M. A. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101980 · Cited by 14
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
Roosan, M. R., Mambetsariev, I., Pharaon, R. R., Fricke, J., Baroz, A. R., Chao, J., Chen, C., Nasser, M. W., Chirravuri‐Venkata, R., Jain, M., et al. (2021) · Cancers · doi:10.3390/cancers13112776 · Cited by 11
Alarcón‐Sánchez, B. R., Pérez‐Carreón, J. I., Villa‐Treviño, S., & Arellanes‐Robledo, J. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114818 · Cited by 12
Xu, F., Dong, M.-M., Wang, Z., & Cao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1083069 · Cited by 14
Xu, M., Liu, X., Zhou, X., Qin, Y.-L., Yang, L., Wen, S., Qiu, Y., Chen, S., Tang, R., Guo, Y.-T., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106964 · Cited by 10
Ye, J., Zhang, J., & Ding, W. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00203 · Cited by 13
Huang, J., Jin, S., Guo, R., Wu, W., Yang, C., Qin, Y., Chen, Q., He, X., Qu, J., & Yang, Z. (2024) · RNA · doi:10.1261/rna.079865.123 · Cited by 11
Wang, H., Zhang, L., Huang, J., Yang, Z., Chen, F., Yuan, L., Zhao, H., Zhang, Z., & Liu, X. (2024) · Biomedical Optics Express · doi:10.1364/boe.518957 · Cited by 11
Zheng, M., Kumar, A., Sharma, V., Behl, T., Sehgal, A., Wal, P., Shinde, N. V., Kawaduji, B. S., Kapoor, A., Anwer, M. K., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1353860 · Cited by 14
Targeting SWI/SNF ATPases reduces neuroblastoma cell plasticity
Xu, M., Hong, J. J., Zhang, X., Sun, M. H., Liu, X., Kang, J., Stack, H. G., Fang, W., Lei, H., Lacoste, X., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00206-1 · Cited by 11
Emerging roles of cancer-associated histone mutations in genomic instabilities
Yadav, P., Jain, R., & Yadav, R. K. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1455572 · Cited by 11
Wang, Q., Chen, M., Yang, B. J., Zheng, W., Liu, X., & Jian, G. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113766 · Cited by 14
Li, Z., Peluffo, G., Stevens, L. E., Qiu, X., Seehawer, M., Tawawalla, A., Huang, X.-Y., Egri, S. B., Raval, S., McFadden, M., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02197-z · Cited by 12
Yates, J., Mathey-Andrews, C. A., Park, J., Garza, A., Gagné, A., Hoffman, S. E., Bi, K., Titchen, B. M., Hennessey, C. J., Remland, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102188 · Cited by 11
Insights into novel emerging epigenetic drugs in myeloid malignancies
Chandhok, N. S., & Prébet, T. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719866081 · Cited by 11
Xia, M., Chen, H., Chen, T., Xue, P., Dong, X., Lin, Y., Ma, D., Zhou, W., Shi, W., & Li, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766656 · Cited by 11
Khouly, I., López, S. P., Díaz‐Prado, S., Ferrantino, L., Kalm, J., Larsson, L., & Asa’ad, F. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19021020 · Cited by 11
Gaultier, C., Foppolo, S., & Maurange, C. (2022) · Science Advances · doi:10.1126/sciadv.abi4529 · Cited by 11
Chang, M. R., Rusanov, D. A., Arakelyan, J., Alshehri, M. M., Asaturova, A. V., Kireeva, G. S., Babak, M. V., & Ang, W. H. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214923 · Cited by 11
Khoury, L. Y. E., Pan, X., Hlady, R. A., Wagner, R. T., Shaikh, S., Wang, L., Humphreys, M. R., Castle, E. P., Stanton, M., Ho, T. H., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01471-3 · Cited by 11
Carr, C. E., Ganugula, R., Shikiya, R. A., Soto, A. M., & Marky, L. A. (2017) · Biochimie · doi:10.1016/j.biochi.2017.12.008 · Cited by 11
Decoding genetic and epigenetic information embedded in cell free DNA with adapted SALP‐seq
Wu, J., Dai, W., Wu, L., Li, W., Xia, X., & Wang, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32206 · Cited by 11
Wnuk, K., Sudol, J., Givechian, K. B., Soon‐Shiong, P., Rabizadeh, S., Szeto, C. W., & Vaske, C. J. (2019) · iScience · doi:10.1016/j.isci.2019.09.018 · Cited by 10
Zi, Z., Zhang, Y., Zhang, P., Ding, Q., Chu, M., Chen, Y., Minna, J. D., & Yu, Y. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00694 · Cited by 11
Moon, S. W., Son, H. J., Mo, H. Y., Choi, E. J., Yoo, N. J., & Lee, S. H. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153354 · Cited by 11
Kavehei, A., Gore, D. B., Chariton, A. A., & Hose, G. C. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.131899 · Cited by 11
Cell-type switches induced by stochastic histone modification inheritance
Huang, R., Lei, J., & Pei-Yuan, Z. (2019) · Discrete and Continuous Dynamical Systems - B · doi:10.3934/dcdsb.2019074 · Cited by 12
Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors
Ge, M., Li, D., Qiao, Z., Sun, Y., Kang, T., Zhu, S., Wang, S., Xiao, H., Zhao, C., Shen, S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01408-7 · Cited by 11
Recalde, M., Gárate-Rascón, M., Herranz, J. M., Elizalde, M., Azkona, M., Unfried, J. P., Boix, L., Reig, M., Sangro, B., Fernández-Barrena, M. G., et al. (2022) · Cancers · doi:10.3390/cancers14092048 · Cited by 14
Charting single-cell lineages with synthetic and natural barcodes
Rodriguez-Fraticelli, A., & Parreno, V. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-00943-5 · Cited by 11
OCRDetector: Accurately Detecting Open Chromatin Regions via Plasma Cell-Free DNA Sequencing Data
Wang, J., Chen, L., Zhang, X., Tong, Y., & Zheng, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115802 · Cited by 10
From Exercise Physiology to Network Physiology of Exercise
Balagué, N., García‐Retortillo, S., Hristovski, R., & Ivanov, P. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102756 · Cited by 12
Namitz, K. E. W., Tan, S., & Cosgrove, M. S. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.102874 · Cited by 15
Mapping the dynamics of epigenetic adaptation in S. pombe during heterochromatin misregulation
Larkin, A., Kunze, C., Seman, M., Levashkevich, A., Curran, J., Morris-Evans, D., Lemieux, S., Khalil, A. S., & Ragunathan, K. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.07.006 · Cited by 10
Wu, P. V., Fish, M., Hazard, F. K., Zhu, C., Vennam, S., Walton, H., Wagh, D. A., Coller, J., Przybył, J., Morri, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53802-4 · Cited by 8
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications
Tost, J., Aksoy, S. A., Campa, D., Corradi, C., Farinella, R., Ibáñez‐Costa, A., Dubrot, J., Earl, J., Melian, E. B., Kataki, A., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.01.003 · Cited by 11
Metadata
- Authors
- Flavahan, W. A., Gaskell, E., & Bernstein, B. E.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Bernstein, Bradley E.
- Venue
- Science
- Published
- 2017-07-21
- Volume
- 357
- Issue
- 6348
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5940341
- OpenAlex
- W2737272162
- Cited by
- 1,340
- References
- 117
- Citations by year
- 2026: 142 · 2025: 127 · 2024: 156 · 2023: 168 · 2022: 160 · 2021: 188 · 2020: 174 · 2019: 128 · 2018: 80 · 2017: 15
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (award310374, DP1CA216873)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic plasticity, cancer hallmarks, chromatin, epigenetic landscape, tumor suppressor, oncogene activation, cell fate transitions, tumor evolution, tumor initiation, driver mutations, cell differentiation
- MeSH terms
- Chromatin, Humans, Neoplasms, Oncogenes, DNA Methylation, Epigenesis, Genetic, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review